Pfizer/Neurocrine File First Indiplon NDA With Eye On Q4 2005 Launch
Executive Summary
The first of two NDA filings for Pfizer/Neurocrine's insomnia agent indiplon puts the drug on track for a launch in the fourth quarter of 2005
You may also be interested in...
Pfizer Indiplon “Refuse To File” For eNDA May Stem From Shift In FDA Oversight
FDA's shift of responsibilities for Pfizer/Neurocrine's insomnia drug indiplon between review divisions may have led to the agency's delay in accepting the NDA
Pfizer Indiplon “Refuse To File” For eNDA May Stem From Shift In FDA Oversight
FDA's shift of responsibilities for Pfizer/Neurocrine's insomnia drug indiplon between review divisions may have led to the agency's delay in accepting the NDA
Sepracor Estorra (correction)
Sepracor's pending insomnia agent Estorra (eszopiclone) is a single-isomer version of zopiclone (Sanofi-Aventis' Imovane). "The Pink Sheet" incorrectly reported Estorra's generic name (1"The Pink Sheet" Oct. 25, 2004, p. 33)...